Clinical features and treatment results of Fuchs uveitis syndrome

Semir YARIMADA, (Ege Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İzmir, Türkiye)
Mine BARIŞ, (Ege Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İzmir, Türkiye)
Cumali DEĞİRMENCİ, (Ege Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İzmir, Türkiye)
halil ates, (Ege Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İzmir, Türkiye)
Suzan GÜVEN YILMAZ (Ege Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, İzmir, Türkiye)
European eye research
0 0
Yıl: 2022 Cilt: 2 Sayı: 1 Sayfa Aralığı: 9 - 15 Metin Dili: İngilizce DOI: 10.14744/eer.2022.02886 İndeks Tarihi: 03-05-2023

Clinical features and treatment results of Fuchs uveitis syndrome

Öz:
Purpose: The study aims to evaluate the clinical features and treatment results of patients with Fuchs uveitis syndrome (FUS). Methods: A retrospective chart review was carried out for all the FUS patients who were treated and followed up at the Uvea Unit of our clinic between 2008 and 2019. Demographic data of all patients and best corrected visual acuity (BCVA), intraocular pressure (IOP) values, anterior and posterior segment examination findings at the time of diagnosis, and the complications along with medical and surgical treatments were analyzed. Results: The mean age of 56 patients included in the study was 40.19±9.69 (20–66) years and the mean follow-up period was 25.91±33.86 (1–154) months. The mean BCVA was 0.43±0.73 (0–3.1) LogMAR, and the mean IOP value was 17.75±9.64 (8–52) mmHg. At the time of admission, 19.6% patients were under systemic immunosuppressive treatment with corticosteroid and/or immunomodulator agents. The most common presenting symptoms were visual disturbance and blurriness (39.2%). Moreover, the most common complications were cataracts (53.5%) and IOP elevation (26.7%). Phacoemulsification was performed in 50% of eyes with cataracts, and BCVA showed a statistically significant increase postoperatively (p<0.0001). While pressure could be controlled with medical treatment in 73.3% of eyes with high IOP, 26.7% of eyes required glaucoma surgery. BCVA was found <2.10 logMAR in 20% eyes with glaucoma at the last visit. Conclusion: In eyes with FUS, the most common presenting symptom was visual loss and blurriness and the most common complications were cataract and IOP elevation. While the surgical treatment of cataracts can be successfully performed, blindness may develop in eyes with glaucoma despite treatment. Therefore, early diagnosis is essential to prevent unnecessary steroid use in these cases.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Fuchs EI. Ueber komplikationen der heterochromie. Ophthalmologica 1906;15:191–212.
  • 2. Accorinti M, Spinucci G, Pirraglia MP, Bruschi S, Pesci FR, Iannetti L. Fuchs’ heterochromic iridocyclitis in an italian tertiary referral centre: Epidemiology, clinical features, and prognosis. J Ophthalmol 2016;2016:1458624.
  • 3. Daas L, Seitz B, Pleyer U. Fuchs uveitis. Ophthalmologe 2017;114:481–92.
  • 4. Yalcindag FN, Ozdal PC, Ozyazgan Y, Batıoğlu F, Tugal-Tutkun I, BUST Study Group. Demographic and clinical characteristics of uveitis in Turkey: The first national registry report. Ocul Immunol Inflamm 2018;26:17–26.
  • 5. Sun Y, Ji Y. A literature review on fuchs uveitis syndrome: An update. Surv Ophthalmol 2020;65:133–43.
  • 6. Gonzales JA, Hinterwirth A, Shantha J, Wang K, Zhong L, Cummings SL, et al. Association of ocular inflammation and rubella virus persistence. JAMA Ophthalmol 2019;137:435–8.
  • 7. Ruokonen PC, Metzner S, Ucer A, Torun N, Hofmann J, Pleyer U. Intraocular antibody synthesis against rubella virus and other microorganisms in Fuchs’ heterochromic cyclitis. Graefes Arch Clin Exp Ophthalmol 2010;248:565–71.
  • 8. Sabhapandit S, Murthy SI, Balne PK, Sangwan VS, Sumanth V, Reddy AK. Clinical spectrum, diagnostic criteria, and polymerase chain reaction of aqueous humor in viral and toxoplasma detection in Fuchs’ uveitis syndrome. Indian J Ophthalmol 2016;64:555–8.
  • 9. Kreps EO, Derveaux T, De Keyser F, Kestelyn P. Fuchs’ uveitis syndrome: No longer a syndrome? Ocul Immunol Inflamm 2016;24:348–57.
  • 10. Li H, Hou S, Du L, Zhou Q, Kijlstra A, Liu Q. Polymorphisms of TNFAIP3 gene in a Chinese Han population with fuchs heterochromic iridocyclitis. Ophthalmic Genet 2014;35:63–7.
  • 11. Spriewald BM, Lefter C, Huber I, Lauer B, Wenkel H. A suggestive association of fuchs heterochromic cyclitis with cytotoxic T cell antigen 4 gene polymorphism. Ophthalmic Res 2007;39:116–20.
  • 12. Cimino L, Boiardi L, Aldigeri R, Casali B, Nicoli D, Farnetti E, et al. G/R 241 polymorphism of intercellular adhesion molecule 1 (ICAM-1) is associated with Fuchs uveitis. Invest Ophthalmol Vis Sci 2010;51:4447–50.
  • 13. Zhou Q, Kijlstra A, Hou S, Yu H, Zhang X, Li X, et al. Lack of association of miR-146a and Ets-1 gene polymorphisms with Fuchs uveitis syndrome in Chinese Han patients. Mol Vis 2012;18:426–30.
  • 14. Abano JM, Galvante PR, Siopongco P, Dans K, Lopez J. Review of epidemiology of uveitis in Asia: Pattern of uveitis in a tertiary hospital in the Philippines. Ocul Immunol Inflamm 2017;25:S75−80.
  • 15. Arellanes-Garcia L, del Carmen Preciado-Delgadillo M, Recillas- Gispert C. Fuchs’ heterochromic iridocyclitis: Clinical manifestations in dark-eyed Mexican patients. Ocul Immunol Inflamm 2002;10:125–31.
  • 16. Velilla S, Dios E, Herreras JM, Calonge M. Fuchs’ heterochromic iridocyclitis: A review of 26 cases. Ocul Immunol Inflamm 2001;9:169–75.
  • 17. Nalcacioglu P, Cakar Ozdal P, Simsek M. Clinical characteristics of Fuchs’ uveitis syndrome. Turk J Ophthalmol 2016;46:52–7.
  • 18. Tugal-Tutkun I, Guney-Tefekli E, Kamaci-Duman F, Corum I. A cross-sectional and longitudinal study of Fuchs uveitis syndrome in Turkish patients. Am J Ophthalmol 2009;148:510–5. e511.
  • 19. La Hey E, de Vries J, Langerhorst CT, Baarsma GS, Kijlstra A. Treatment and prognosis of secondary glaucoma in Fuchs’ heterochromic iridocyclitis. Am J Ophthalmol 1993;116:327–40.
  • 20. Fearnley IR, Rosenthal AR. Fuchs’ heterochromic iridocyclitis revisited. Acta ophthalmol Scand 1995;73:166–70.
  • 21. Jones NP. Glaucoma in Fuchs’ heterochromic uveitis: Aetiology, management and outcome. Eye (London, England) 1991;5:662–7.
  • 22. Liesegang TJ. Clinical features and prognosis in Fuchs’ uveitis syndrome. Arch Ophthalmol 1982;100:1622–6.
  • 23. Saari KM. Uveitis Update: Proceedings of the First International Symposium on Uveitis held in Hanasaari, Espoo, Finland. Vol. 651. Hanasaari, Espoo: Excerpta Medica; 1984.
  • 24. Higuchi M, Ohno S, Matsuda HJ. Clinical characteristics of Fuchs’ heterochromic iridocyclitis. Medscape 1982;36:1275– 80.
  • 25. Yang P, Fang W, Jin H, Li B, Chen X, Kijlstra A. Clinical features of Chinese patients with Fuchs’ syndrome. Ophthalmology 2006;113:473–80.
  • 26. Bawazeer AM. Clinical characteristics of Fuchs’ heterochromic iridocyclitis in a tertiary medical center in Makkah region of Saudi Arabia: A retrospective study. J Taib Univ Med Sci 2014;9:65–8.
  • 27. Al-Mansour YS, Al-Rajhi AA, Al-Dhibi H, Abu El-Asrar AM. Clinical features and prognostic factors in Fuchs’ uveitis. Int Ophthalmol 2010;30:501–9.
  • 28. Zarei M, Darabeigi S, Mehrpour M, Roohipoor R, Ghassemi H, Ebrahimiadib N. Fuchs’ Uveitis in Iranian patients: A review of 89 eyes. Ocul Immunol Inflamm 2019;27:1077–85.
  • 29. Parrat E, Brousse D, Cousin P, L’Herron F, Touameur S, Charpentier D, et al. Fuchs’ uveitic syndrome in a patient with ocular toxoplasmosis. J Fr Ophtalmol 1999;22:1067–71.
  • 30. Ganesh SK, Sharma S, Narayana KM, Biswas J. Fuchs’ heterochromic iridocyclitis following bilateral ocular toxoplasmosis. Ocular Immunol Inflamm 2004;12:75–7.
  • 31. Teyssot N, Cassoux N, Lehoang P, Bodaghi B. Fuchs heterochromic cyclitis and ocular toxocariasis. Am J Ophthalmol 2005;139:915–6.
  • 32. Toniolo JT, Hall AJ, Smith JG, Levy J, Lim LL. Risk factors for glaucoma in a cohort of patients with fuchs heterochromic iridocyclitis. Ocul Immunol Inflamm 2017;25:753–9.
  • 33. Tandon M, Malhotra PP, Gupta V, Gupta A, Sharma A. Spectrum of Fuchs uveitic syndrome in a North Indian population. Ocul Immunol Inflamm 2012;20:429–33.
  • 34. Bouchenaki N, Herbort CP. Fluorescein angiographic findings and clinical features in Fuchs’ uveitis. Int Ophthalmol 2010;30:511–9.
APA Yarımada S, Esen Baris M, DEĞİRMENCİ C, ates h, Guven Yılmaz S (2022). Clinical features and treatment results of Fuchs uveitis syndrome. , 9 - 15. 10.14744/eer.2022.02886
Chicago Yarımada Semir,Esen Baris Mine,DEĞİRMENCİ Cumali,ates halil,Guven Yılmaz Suzan Clinical features and treatment results of Fuchs uveitis syndrome. (2022): 9 - 15. 10.14744/eer.2022.02886
MLA Yarımada Semir,Esen Baris Mine,DEĞİRMENCİ Cumali,ates halil,Guven Yılmaz Suzan Clinical features and treatment results of Fuchs uveitis syndrome. , 2022, ss.9 - 15. 10.14744/eer.2022.02886
AMA Yarımada S,Esen Baris M,DEĞİRMENCİ C,ates h,Guven Yılmaz S Clinical features and treatment results of Fuchs uveitis syndrome. . 2022; 9 - 15. 10.14744/eer.2022.02886
Vancouver Yarımada S,Esen Baris M,DEĞİRMENCİ C,ates h,Guven Yılmaz S Clinical features and treatment results of Fuchs uveitis syndrome. . 2022; 9 - 15. 10.14744/eer.2022.02886
IEEE Yarımada S,Esen Baris M,DEĞİRMENCİ C,ates h,Guven Yılmaz S "Clinical features and treatment results of Fuchs uveitis syndrome." , ss.9 - 15, 2022. 10.14744/eer.2022.02886
ISNAD Yarımada, Semir vd. "Clinical features and treatment results of Fuchs uveitis syndrome". (2022), 9-15. https://doi.org/10.14744/eer.2022.02886
APA Yarımada S, Esen Baris M, DEĞİRMENCİ C, ates h, Guven Yılmaz S (2022). Clinical features and treatment results of Fuchs uveitis syndrome. European eye research, 2(1), 9 - 15. 10.14744/eer.2022.02886
Chicago Yarımada Semir,Esen Baris Mine,DEĞİRMENCİ Cumali,ates halil,Guven Yılmaz Suzan Clinical features and treatment results of Fuchs uveitis syndrome. European eye research 2, no.1 (2022): 9 - 15. 10.14744/eer.2022.02886
MLA Yarımada Semir,Esen Baris Mine,DEĞİRMENCİ Cumali,ates halil,Guven Yılmaz Suzan Clinical features and treatment results of Fuchs uveitis syndrome. European eye research, vol.2, no.1, 2022, ss.9 - 15. 10.14744/eer.2022.02886
AMA Yarımada S,Esen Baris M,DEĞİRMENCİ C,ates h,Guven Yılmaz S Clinical features and treatment results of Fuchs uveitis syndrome. European eye research. 2022; 2(1): 9 - 15. 10.14744/eer.2022.02886
Vancouver Yarımada S,Esen Baris M,DEĞİRMENCİ C,ates h,Guven Yılmaz S Clinical features and treatment results of Fuchs uveitis syndrome. European eye research. 2022; 2(1): 9 - 15. 10.14744/eer.2022.02886
IEEE Yarımada S,Esen Baris M,DEĞİRMENCİ C,ates h,Guven Yılmaz S "Clinical features and treatment results of Fuchs uveitis syndrome." European eye research, 2, ss.9 - 15, 2022. 10.14744/eer.2022.02886
ISNAD Yarımada, Semir vd. "Clinical features and treatment results of Fuchs uveitis syndrome". European eye research 2/1 (2022), 9-15. https://doi.org/10.14744/eer.2022.02886
Sayfa Oluşturulma Tarihi
24-04-2024 6:39

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları